Maro Ohanian, MD, DO

• Acute Myeloid Leukemia

As Associate Professor Clinical Faculty (CFA) in the Department of Leukemia at MD Anderson Cancer Center, Dr. Maro Ohanian is board-certified in Internal Medicine, Medical Oncology, and Hematology. Her focus is clinical care and clinical research for patients with acute and chronic forms of leukemia. Dr. Ohanian conducts clinical trials with the goal of improving survival outcomes of patients, reducing toxicity and complications during treatment, and with consideration for cost-effective treatments that are accessible to patients from all walks of life. As the Principal Investigator of several clinical trials focused on targeting a variety of molecular pathways, she is committed to personalized approaches to leukemia treatment and improving supportive care strategies for leukemia patients. Because toxic metals are a modifiable risk factor associated with increased cancer risk, and because they can be directly targeted with metal detoxifying agents, Dr. Ohanian is conducting lab studies of metal analysis in AML as a novel cancer prevention and treatment method. She is also conducting clinical trials of metal detoxification during MDS and AML therapy to reverse the carcinogenic effects of metals. She is committed to this research because she sees the promise it holds for revolutionizing the fields of cancer prevention and treatment. Dr. Ohanian has strong collaborations with world-leaders in cancer prevention and research. She is the recipient of the American Journal of Hematology Young Investigator Award for her innovative research that defined the basis of understanding metals as a therapeutic target for cancer prevention.